<DOC>
	<DOC>NCT00783328</DOC>
	<brief_summary>To evaluate safety and tolerability of PF-00299804 in Japanese patients with advanced malignant solid tumors at doses up to the clinically recommended phase 2 dose in non-Japanese studies.</brief_summary>
	<brief_title>A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Malignant solid tumor with no currently approved treatment Adequate functions Bone Marrow, Renal, Liver and Cardiac Any surgery, radiotherapy within 4 weeks of baseline disease assessments Clinically significant abnormalities of the cornea Patients with symptomatic brain/central nerve system metastases Any clinically significant gastrointestinal abnormalities Uncontrolled or significant cardiovascular disease Patients with significant interstitial pneumonia or pulmonary fibrosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>solid tumor</keyword>
</DOC>